Fundraising Fox
/Companies
Sign in

Calder Biosciences

NYC, US · Founded 2018 · 4 employees on LinkedIn · 1 known investors

Find your way into Calder Biosciences

Sign up to see every warm intro you have to Calder Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Calder Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Calder Biosciences develops protein-based subunit vaccines using its 3D-Vaxlock technology, which uses dityrosine crosslinking to lock immunogens into the shape they hold on a virus surface for improved antibody responses. Its engineered immunogens aim to offer better safety, efficacy, thermostability, and reduced cold chain requirements against infectious diseases.

BiotechHealthtechMedical Devices

Founders & leadership

Calder Biosciences was founded in 2018 by Christopher Marshall and Mark A. Yondola.

CMChristopher Marshall
Christopher MarshallFounder & CEOChristopher Marshall holds a Ph.D. in biomedical research from Rockefeller University and has founded multiple biotechnology companies, including Ophidion (addressing neurological and pain conditions) and Avatar Biotechnologies (focused on enzymes and protein technologies), before founding Calder Biosciences to develop protein-based subunit vaccines. He previously worked as a management consultant at Oliver Wyman & Co. on risk management and strategy projects for European financial institutions and is a registered USPTO patent agent.
MAMark A. Yondola
Mark A. YondolaFounder & Chief Science OfficerMark Yondola brings over 15 years of experience in protein engineering and vaccine design, with expertise in CMC process design, analytical characterization, and CDMO management for protein biologics. As Founder and Chief Science Officer of Calder Biosciences, he leads development of protein-based vaccines using the company's 3D-Vaxlock technology platform.
DPDirk Pleimes
Dirk PleimesChief Medical OfficerDirk Pleimes held roles as Chief Medical Officer and Chief Scientific Officer before becoming Chief Executive Officer at Calder Biosciences, bringing experience across drug development from early-stage science through clinical translation.

Investors · 1

Related companies · 1

Coya TherapeuticsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.

Companies working in the same space as Calder Biosciences.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2.9M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$299.7K
National Institutes of Health (NIH)National Institutes of HealthPhase II2018$2.9M
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$599.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Calder Biosciences do?
Calder Biosciences develops protein-based subunit vaccines using its 3D-Vaxlock technology, which uses dityrosine crosslinking to lock immunogens into the shape they hold on a virus surface for improved antibody responses. Its engineered immunogens aim to offer better safety, efficacy, thermostability, and reduced cold chain requirements against infectious diseases.
Who founded Calder Biosciences?
Calder Biosciences was founded by Christopher Marshall, Mark A. Yondola in 2018.
Who are Calder Biosciences's investors?
Calder Biosciences's investors include SOSV.
Where is Calder Biosciences headquartered?
Calder Biosciences is headquartered in NYC, US.